Abstract: Provided herein are pharmaceutical compositions (e.g., oral dosage formulations) comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent. Also provided herein are methods of preparing and methods of using the pharmaceutical compositions.
Type:
Grant
Filed:
January 8, 2020
Date of Patent:
October 10, 2023
Assignee:
Celgene Corporation
Inventors:
Anjali Agrawal, Ming J. Chen, Shyam Babu Karki, Prajwal Gunwanth Thool, Dora Visky, Ruimin Xie
Abstract: Provided herein are methods for the treatment of bone disorders that are associated with kidney disease wherein the methods comprise administration of Activin-ActRIIA inhibitors to a subject in need of the treatment. Also provided herein are methods and compositions for the treatment of low turnover bone disorders wherein the methods comprise administration of Activin-ActRIIA inhibitors to a subject in need of the treatment. Further provided herein are compositions for the treatment of bone disorders that are associated with kidney disease and compositions for the treatment of low turnover bone disorders and vascular calcification.
Type:
Application
Filed:
January 18, 2023
Publication date:
September 21, 2023
Applicants:
Celgene Corporation, Washington University
Inventors:
Victoria Sung, Randall Stevens, William Smith, Victor Schorr Sloan, Keith Hruska, Yifu Fang
Abstract: Provided herein are piperidine dione compounds having the following structure: wherein R1, R2, R3, R4, L, V, X, a and m are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.
Type:
Grant
Filed:
June 23, 2021
Date of Patent:
August 29, 2023
Assignee:
Celgene Corporation
Inventors:
Matthew D. Alexander, Matthew D. Correa, Deepak Dalvie, Virginia Heather Sharron Grant, Joshua Hansen, Roy L. Harris, III, Evan J. Horn, Dehua Huang, Christopher Mayne, Stephen Norris, Veronique Plantevin-Krenitsky, John J. Sapienza, Lida Tehrani, Brandon W. Whitefield
Abstract: Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
Type:
Grant
Filed:
July 21, 2020
Date of Patent:
August 22, 2023
Assignee:
CELGENE CORPORATION
Inventors:
Brian E. Cathers, Philip Chamberlain, Antonia Lopez-Girona, Gang Lu
Abstract: A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is Compound 1, Compound 2, or Compound 3.
Type:
Grant
Filed:
February 10, 2021
Date of Patent:
August 15, 2023
Assignee:
Celgene Corporation
Inventors:
Maria Soraya Carrancio Anton, Joshua Hansen, Courtney G. Havens, Antonia Lopez-Girona, Gang Lu, Lilly L. Wong
Abstract: Provided are formulations and dosage forms of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide, alternatively named (1s,4s)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide, or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
Type:
Grant
Filed:
December 22, 2020
Date of Patent:
July 18, 2023
Assignee:
Celgene Corporation
Inventors:
Scott Bone, Tracy Lee Gaebele, Yu Pu, Lianfeng Huang
Abstract: Provided herein are crystalline forms of (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate. Pharmaceutical compositions comprising crystalline forms of (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate are also disclosed.
Type:
Grant
Filed:
June 3, 2021
Date of Patent:
June 20, 2023
Assignees:
Celgene Corporation, Lundbeck La Jolla Research Center, Inc.
Abstract: Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, for treating, preventing or managing hematological malignancies.
Type:
Grant
Filed:
October 20, 2020
Date of Patent:
June 6, 2023
Assignee:
Celgene Corporation
Inventors:
Maria Soraya Carrancio Anton, Tonia J. Buchholz, Shailaja Kasibhatla, Antonia Lopez-Girona, Rama Krishna Narla, Michael Pourdehnad
Abstract: Provided herein are methods of using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, in combination with a second active agent for treating, preventing or managing multiple myeloma. The second active agent is one or more of a BTK inhibitor, an mTOR inhibitor, a PIM inhibitor, an IGF-1R inhibitor, an MEK inhibitor, an XPO1 inhibitor, a DOT1L inhibitor, an EZH2 inhibitor, a JAK2 inhibitor, a BRD4 inhibitor, a PLK 1 inhibitor, an NEK2 inhibitor, an AURKB inhibitor, a BIRC5 inhibitor, a BET inhibitor, or a DNA methyltransferase inhibitor.
Abstract: Provided herein are methods of using compounds and compositions for treating, managing, and/or preventing systemic lupus erythematosus (SLE). Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.
Abstract: Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.
Type:
Grant
Filed:
September 2, 2021
Date of Patent:
May 23, 2023
Assignee:
Celgene Corporation
Inventors:
Markian S. Jaworsky, Roger Shen-Chu Chen, George W. Muller
Abstract: Provided herein are methods of treatment of AML comprising administering 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in a combination therapy.
Type:
Application
Filed:
March 12, 2021
Publication date:
May 18, 2023
Applicant:
Celgene Corporation
Inventors:
Tonia J. BUCHHOLZ, Nian GONG, Jinhong FAN, Emily PACE, Daniel W. PIERCE, Michael POURDEHNAD, Tsun-Wen YAO
Abstract: Provided herein are methods for the treatment in a subject of anemia, anemia requiring RBC transfusion, low or intermediate- 1 -risk myelodysplastic syndromes (MDS), and/or non-proliferative chronic myelomonocytic leukemia (CMML) in any mammals wherein the methods comprise administration of Activin-ActRII signaling inhibitors to a subject in need of the treatment.
Type:
Application
Filed:
September 14, 2022
Publication date:
May 11, 2023
Applicant:
Celgene Corporation
Inventors:
Kenneth M. Attie, Christopher Rovaldi, Abderrahmane Laadem
Abstract: A complex comprises a CRBN having a europium-anti-his antibody on the N-terminus of the CRBN, and a Cy5-conjugated small molecule, wherein the Cy5-conjugated small molecule binds the CRBN, and uses thereof for identifying therapeutic compounds.
Type:
Grant
Filed:
September 18, 2020
Date of Patent:
May 9, 2023
Assignee:
CELGENE CORPORATION
Inventors:
Philip Paul Chamberlain, Mary Matyskiela, Godrej Khambatta
Abstract: Provided herein are piperidine dione compounds having the following structure: wherein RN, R1, R2, R3, R4, RN, L, V, X, a, m, and n are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.
Type:
Grant
Filed:
June 23, 2021
Date of Patent:
April 25, 2023
Assignee:
Celgene Corporation
Inventors:
Matthew D. Alexander, Matthew D. Correa, Deepak Dalvie, Virginia Heather Sharron Grant, Joshua Hansen, Roy L. Harris, III, Evan J. Horn, Dehua Huang, Christopher Mayne, Stephen Norris, Veronique Plantevin-Krenitsky, John J. Sapienza, Lida Tehrani, Brandon W. Whitefield
Abstract: Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, alone or in combination with obinutuzumab, for treating, preventing or managing chronic lymphocytic leukemia/small lymphocytic lymphoma.
Type:
Grant
Filed:
October 20, 2020
Date of Patent:
April 18, 2023
Assignee:
Celgene Corporation
Inventors:
Preethi Janardhanan, Shailaja Kasibhatla, Antonia Lopez-Girona, Michael Pourdehnad
Abstract: Computer-implemented systems and methods are provided for constructing a numerical model to generate a probability that a patient diagnosed with multiple myeloma will die within a predetermined period of time. Reference data for a plurality of patients diagnosed with multiple myeloma is received. First variables selected from the reference data are deemed predictive of mortality for a first predetermined period of time, and second variables selected from the reference data are deemed predictive of mortality for a second predetermined period of time. A first computer model comprising a combination of variables of the first selected variables and first weighting factors is generated. A second computer model comprising a combination of variables of the second selected variables and second weighting factors is generated. The first computer model and the second computer model are trained using the reference data to determine numerical values for the respective first and second weighting factors.
Type:
Grant
Filed:
October 30, 2017
Date of Patent:
April 11, 2023
Assignee:
Celgene Corporation
Inventors:
Shankar Swamimalai Srinivasan, Albert Elion-Mboussa
Abstract: The present disclosure relates to engineered polypeptides comprising degradation domains, compounds, compositions, and methods for their preparation and use as for degrading engineered proteins in cells.
Type:
Application
Filed:
August 5, 2022
Publication date:
March 30, 2023
Applicant:
Celgene Corporation
Inventors:
Christopher Walton Carroll, Laura Akullian D'Agostino, Haibo Liu, Veerabahu Shanmugasundaram, Brook Barajas
Abstract: Pharmaceutical compositions and single unit dosage forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as cancer, an inflammatory disease and/or an immune-related disorder.